Pharmacology
-
Exploring the evolving landscape in combination therapies for EGFR-mutated advanced NSCLC
Susan Scott, MD, discussed the findings from the MARIPOSA and FLAURA2 trials and the next steps to identify who may benefit from which regimen.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Navigating new ACR/CHEST guidelines for screening, monitoring, and treatment of SARD-ILD
Authors Jose R. Castellanos, MD; Anthony J. Esposito, MD; and Caroline Zhao, MD, discuss key strategies, including early screening with pulmonary function tests and high-resolution chest tomography, cautious glucocorticoid use, and personalized steroid-sparing treatment.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all […]
